Wed, Dec 17, 3:50 PM, Zacks
Genomic Health's Oncotype DX Positive in Multiple Studies - Analyst Blog
Developer of genomic-based clinical laboratory services, Genomic Health Inc. (GHDX) recently announced positive feedback from the clinical validation study of Oncotype DX in patients with a pre-invasive form of breast cancer known as DCIS.
Wed, Dec 10, 12:30 PM, Zacks
Myriad Genetics Unveils Positive Cancer Study Results - Analyst Blog
Myriad's (MYGN) myChoice Homologous Recombination Deficiency (HRD) test has the ability to predict more accurately the response to platinum-based therapy in patients who are in the early stage of triple negative breast cancer (TNBC).